Crescita Therpeutc J (TSE:CTX)
TSX:CTX
Want to see TSE:CTX full AI Analyst Report?
CTX Stock Chart & Stats
C$0.47
-C$0.02(-3.39%)
At close: 4:00 PM EST
C$0.47
-C$0.02(-3.39%)
Day’s Range― - ―
52-Week RangeC$0.40 - C$0.78
Previous CloseN/A
Volume9.50K
Average Volume (3M)12.63K
Market Cap
C$14.15M
Enterprise ValueC$7.94M
Total Cash (Recent Filing)C$8.71M
Total Debt (Recent Filing)C$2.50M
Price to Earnings (P/E)―
Beta-0.80
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding18,613,937
10 Day Avg. Volume2,470
30 Day Avg. Volume12,630
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)0.58
Price to Sales (P/S)0.43
P/FCF Ratio12.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & Strong Gross MarginConsistent TTM revenue growth combined with ~52% gross margins indicates durable product economics and demand. Strong top-line expansion and healthy unit margins support reinvestment in R&D and commercialization, improving the odds of sustained operating leverage over months.
Improving Cash Generation (Positive FCF)Transition to positive operating and free cash flow with large FCF growth shows improving internal funding capacity. Durable cash generation reduces reliance on external financing, enabling organic funding of development/operations and increasing resilience through 2–6 month horizons.
Conservative Balance Sheet / Low LeverageLow leverage and a sizable equity base provide a structural cushion for the capital-intensive specialty pharma profile. Conservative financing improves flexibility to weather clinical or market setbacks and supports continued investment without excessive solvency risk.
Bears Say
Negative Profitability (EBIT & Net Income)Ongoing negative EBIT and net income mean the company has not yet converted revenue growth into consistent profits. This structural profitability gap can limit retained earnings for R&D or commercialization and leaves long-term return generation uncertain.
Inconsistent Cash Flow History And Low CoverageWhile FCF turned positive recently, past periods of negative operating and free cash flow and a low coverage ratio point to inconsistent cash conversion. This structural variability raises the probability of needing external funding in stress periods, limiting strategic optionality.
Negative Return On EquityA persistently negative ROE indicates the company’s capital base has not delivered shareholder returns. Over the medium term, this undermines confidence in management’s ability to generate scalable profits and can impair access to favorable financing terms.
Crescita Therpeutc News
CTX FAQ
What was Crescita Therpeutc J’s price range in the past 12 months?
Crescita Therpeutc J lowest stock price was C$0.40 and its highest was C$0.78 in the past 12 months.
What is Crescita Therpeutc J’s market cap?
Crescita Therpeutc J’s market cap is C$14.15M.
When is Crescita Therpeutc J’s upcoming earnings report date?
Crescita Therpeutc J’s upcoming earnings report date is Aug 12, 2026 which is in 83 days.
How were Crescita Therpeutc J’s earnings last quarter?
Crescita Therpeutc J released its earnings results on May 11, 2026. The company reported -C$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.06.
Is Crescita Therpeutc J overvalued?
According to Wall Street analysts Crescita Therpeutc J’s price is currently Overvalued.
Does Crescita Therpeutc J pay dividends?
Crescita Therpeutc J does not currently pay dividends.
What is Crescita Therpeutc J’s EPS estimate?
Crescita Therpeutc J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescita Therpeutc J have?
Crescita Therpeutc J has 18,613,937 shares outstanding.
What happened to Crescita Therpeutc J’s price movement after its last earnings report?
Crescita Therpeutc J reported an EPS of -C$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.299%.
Which hedge fund is a major shareholder of Crescita Therpeutc J?
Currently, no hedge funds are holding shares in TSE:CTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Crescita Therpeutc J
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
Technical Analysis
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―